Skip to main content
ADTX
NASDAQ Life Sciences

Aditxt Receives Nasdaq Extension to Regain Listing Compliance, Must Secure Financing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.964
Mkt Cap
$541.486K
52W Low
$0.704
52W High
$4,463.46
52W Position info
37% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ADTX sits 37% above its 52-week low of $0.704 on light trading volume (0.1× avg).

Summary

Aditxt, Inc. has been granted an extension by Nasdaq until May 15, 2026, to regain compliance with listing rules, contingent on completing financing transactions.


Key Events · Corporate Governance and Compliance · ADTX

  • Nasdaq Extension Granted

    Aditxt, Inc. received an extension from Nasdaq to regain compliance with Listing Rule 5550(b), which requires minimum stockholders' equity, market value of listed securities, or net income.

  • Conditions for Compliance

    The extension is conditional on the company completing financing transactions and submitting a public report by May 15, 2026, demonstrating compliance.

  • Delisting Risk Remains

    Failure to evidence compliance by the periodic report for the period ending June 30, 2026, could result in delisting, though the company retains appeal rights.


Analysis · ADTX · Life Sciences

This 8-K filing indicates that Aditxt, Inc. has secured a temporary reprieve from Nasdaq regarding its non-compliance with listing rules. While the extension prevents immediate delisting, it underscores the company's precarious financial position, requiring significant financing to meet the minimum equity, market value, or net income requirements. For a company with a very low market capitalization, maintaining a Nasdaq listing is critical for investor visibility and access to capital. The need to complete financing transactions by May 15, 2026, introduces a tight deadline and significant execution risk. Investors should monitor the company's progress on securing financing and its ability to demonstrate compliance, as failure could lead to delisting and further pressure on the stock.

At the time of this filing, ADTX was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $541.5K. The 52-week trading range was $0.70 to $4,463.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADTX - Latest Insights

ADTX
Jul 17, 2026, 12:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0025
Real-time Price: $0.0035 info
Change: +$0.0010 (+40%) info
Market Cap: $3.593M info
ADTX
Jun 24, 2026, 11:36 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.050599
Real-time Price: $0.0035 info
Change: -$0.047099 (-93%) info
Market Cap: $3.593M info
ADTX
Jun 24, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.0406
Real-time Price: $0.0035 info
Change: -$0.0371 (-91%) info
Market Cap: $3.593M info
ADTX
Jun 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.0443
Real-time Price: $0.0035 info
Change: -$0.0408 (-92%) info
Market Cap: $3.593M info
ADTX
Jun 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0445
Real-time Price: $0.0035 info
Change: -$0.041 (-92%) info
Market Cap: $3.593M info